Sponsors (3)
The bill clarifies Part D discount rules and reduces manufacturer discount obligations for certain oral NDA drugs, but does so at the likely cost of higher out-of-pocket expenses for Medicare beneficiaries and shifted fiscal burdens and complexity for public programs and beneficiaries.
State and federal program administrators (CMS and state governments) get clearer, more consistent Part D discount rules by aligning Part D discount definitions with specific Medicaid reclassification decisions, reducing administrative ambiguity.
Manufacturers of certain orally administered NDA drugs will no longer have to provide Part D manufacturer discounts for those products, reducing their compliance costs and financial burden.
Medicare Part D enrollees could face higher out-of-pocket costs if excluded drugs no longer trigger manufacturer discounts that lower patient cost-sharing.
The change can shift program savings or rebate burdens between Medicare and Medicaid, potentially increasing federal or state Medicaid costs and producing inconsistent pricing across programs (hurting Medicaid beneficiaries and taxpayers).
Beneficiaries and Part D plan sponsors may face added complexity and confusion determining out-of-pocket responsibility for affected orally administered drugs during the transition.
Based on analysis of 2 sections of legislative text.
Introduced March 6, 2025 by Andrew R. Garbarino · Last progress March 6, 2025
Excludes from the Medicare Part D manufacturer discount program certain orally administered drugs that were approved under an NDA and that CMS has allowed to be reclassified as noninnovator multiple source drugs for Medicaid rebate purposes. The change means manufacturers of those specific oral drugs would not be subject to the Part D manufacturer discount adjustment tied to that program. The amendment changes how CMS and manufacturers treat those drugs for Part D discount obligations and relies on CMS determinations under the Medicaid rebate reclassification process, creating a direct interaction between Medicaid rebate status and Part D discount treatment.